These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 12531619

  • 1. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ.
    Lancet; 2003 Jan 11; 361(9352):183; author reply 183-4. PubMed ID: 12531619
    [No Abstract] [Full Text] [Related]

  • 2. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ, Kolnagou A.
    Lancet; 2003 Jan 11; 361(9352):184. PubMed ID: 12531621
    [No Abstract] [Full Text] [Related]

  • 3. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG.
    Lancet; 2003 Jan 11; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract] [Full Text] [Related]

  • 4. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Fischer R, Engelhardt R.
    Lancet; 2003 Jan 11; 361(9352):182-3; author reply 183-4. PubMed ID: 12531618
    [No Abstract] [Full Text] [Related]

  • 5. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G, Lindeman R.
    Br J Haematol; 2008 Aug 11; 142(4):679-80. PubMed ID: 18537970
    [No Abstract] [Full Text] [Related]

  • 6. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
    Aydinok Y, Nisli G, Kavakli K.
    Br J Haematol; 1999 Jul 11; 106(1):252-3. PubMed ID: 10444196
    [No Abstract] [Full Text] [Related]

  • 7. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D, Loubser MD, Koren G, Roifman CM, Olivieri NF.
    Br J Haematol; 1997 Sep 11; 98(3):597-600. PubMed ID: 9332313
    [Abstract] [Full Text] [Related]

  • 8. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
    Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M.
    Haematologica; 2009 Dec 11; 94(12):1777-8. PubMed ID: 19815834
    [No Abstract] [Full Text] [Related]

  • 9. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
    Pepe A, Meloni A, Pistoia L, Cuccia L, Gamberini MR, Lisi R, D'Ascola DG, Rosso R, Allò M, Spasiano A, Restaino G, Righi R, Mangione M, Positano V, Ricchi P.
    Br J Haematol; 2018 Dec 11; 183(5):783-795. PubMed ID: 30334574
    [Abstract] [Full Text] [Related]

  • 10. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
    Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R.
    Blood; 2006 May 01; 107(9):3738-44. PubMed ID: 16352815
    [Abstract] [Full Text] [Related]

  • 11. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
    Tavecchia L, Masera N, Russo P, Cirò A, Vincenzi A, Vimercati C, Masera G.
    Haematologica; 2006 Jun 01; 91(6 Suppl):ECR19. PubMed ID: 16785138
    [Abstract] [Full Text] [Related]

  • 12. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 01; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

  • 13. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
    Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A.
    Br J Haematol; 2003 Jun 01; 121(6):938-48. PubMed ID: 12786807
    [Abstract] [Full Text] [Related]

  • 14. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
    Porcu M, Landis N, Salis S, Corda M, Orrù P, Serra E, Usai B, Matta G, Galanello R.
    Eur J Heart Fail; 2007 Mar 01; 9(3):320-2. PubMed ID: 17029959
    [Abstract] [Full Text] [Related]

  • 15. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
    Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ.
    J Cardiovasc Magn Reson; 2012 Jan 25; 14(1):8. PubMed ID: 22277065
    [Abstract] [Full Text] [Related]

  • 16. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 17. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR, Martin MB.
    N Engl J Med; 1998 Dec 03; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract] [Full Text] [Related]

  • 18. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 19. Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
    Richardson DR.
    Lancet; 2002 Aug 17; 360(9332):501-2. PubMed ID: 12241649
    [No Abstract] [Full Text] [Related]

  • 20. Long-term trials of deferiprone in Cooley's anemia.
    Olivieri NF, Brittenham GM.
    Ann N Y Acad Sci; 1998 Jun 30; 850():217-22. PubMed ID: 9668542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.